Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 8 von 46

Details

Autor(en) / Beteiligte
Titel
Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms
Ist Teil von
  • Archives of gynecology and obstetrics, 2021-04, Vol.303 (4), p.955-963
Ort / Verlag
Berlin/Heidelberg: Springer Berlin Heidelberg
Erscheinungsjahr
2021
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • Purpose The objective of this study was to evaluate the efficacy of fractional CO 2 laser to manage vulvar and vaginal symptoms of Genitourinary Syndrome of Menopause (GSM) in postmenopausal women. Methods All postmenopausal women with symptoms of GSM undergoing fractional CO 2 laser treatment in our centers were asked to fill out a validated quality of life questionnaire (Global Quality of Life Questionnaire), Visual Analog Scale (VAS) for symptoms, a questionnaire on overall discomfort related to pelvic floor symptoms, and the Female Sexual Function Index (FSFI) at several points: before each session (three sessions at monthly intervals) and one 3 months after treatment completion. Statistical analysis compared pre-therapy data and data at 3 months of treatment. Results Forty-six women were included with a mean age of 57.3 years (± 11.1 years). A significant improvement was demonstrated in vaginal dryness ( p  = 6.34 10 –6 ) and for symptoms of stress urinary incontinence ( p  = 0.043). Among sexually active patients, there was a significant improvement in the degree of symptom discomfort affecting their satisfaction ( p  = 0.007), dyspareunia ( p  = 0.001) and sensitivity during sexual intercourse ( p  = 0.001). Significantly, more women were able to achieve ( p  = 0.026) and maintain ( p  = 0.018) lubrication during intercourse. Conclusion CO 2 laser treatment seems to improve the quality of life and sexual health of patients as well as GSM symptoms at 3 months of treatment; long-term reevaluation is necessary to demonstrate that improvement persists over time.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX